摘要
目的 确定肝癌缺失基因-1 （DLC-1）在人垂体腺瘤巾的表达水平,评估该水平与腺瘤临床病理特征的关联. 方法 选取上海长征医院神经外科自2006年8月至2008年10月间手术中获得的84例垂体腺瘤组织和6例尸检时获得的正常人垂体组织.利用免疫组织化学染色法研究标本中DLC-1、Ki-67的蛋白表达；实时荧光定量PCR的方法研究标本中DLC-1 mRNA表达.结果免疫组织化学染色结果提示D LC -1在垂体腺瘤巾表达减少,Ki-67在垂体腺瘤巾表达增多；Pearson相关分析提示二者呈负相关（r=-0.764,P=.001）.实时荧光定量PCR提示DLC-l mRNA在垂体腺瘤中表达减少,且在侵袭性垂体腺瘤组织中的表达水平明显低于非侵袭性垂体腺瘤,差异有统计学意义（P＜0.05）. 结论 DLC-1的表达下调可能跟垂体腺瘤侵袭性生长有关,可作为分子治疗的新靶点.
Objective To determine the expression level of deleted in liver cancer-1 （DLC-1）gene in human pituitary tumors, and assess the correlation between DLC-1 expression and clinicopathological parameters in these tumors. Methods DLC-1 and Ki-67 protein expressions were analyzed by immunohistochemistry and DLC-1 mRNA expression by quantitative RT-PCR in 84 pituitary adcnomas and 6 normal human adenohypophyses. Results Immunohistochemical results suggested that DLC-1 expression decreased and Ki-67 expression increased in the pituitary adenomas; Pearson correlation analysis showed that they were negatively correlated （r=-0.764,P=0.001）.RT-PCR indicated that DLC-1 mRNA expression decreased in the pituitary adenomas; significantly decreased DLC-1 expression in invasive pituitary adenomas was noted as compared with that in non-invasive ones （P〈0.05）. Conclusion Down-regulation of DLC-1 expression may contribute to the tumorigenesis of pituitary adenomas and DLC-1 can be the new target of molecular therapy.
出处
《中华神经医学杂志》
CAS
CSCD
北大核心
2012年第1期16-19,共4页
Chinese Journal of Neuromedicine
